Q2 2025 Allurion Technologies Inc Earnings Call Transcript
Key Points
- Allurion Technologies Inc (ALUR) is pivoting towards a combination therapy approach that integrates the Allurion program with low-dose GLP-1 therapy, which is expected to improve adherence and efficacy in obesity care.
- The company has retooled its R&D pipeline to focus on innovations that enable seamless combination therapy, including a novel GLP-1 drug-eluting intragastric balloon.
- Allurion Technologies Inc (ALUR) has submitted the fourth and final module of its PMA submission to the FDA, potentially accelerating the approval process for its products in the US market.
- Operating expenses decreased by 48% compared to the prior year, reflecting successful restructuring and reorganization efforts.
- The company reported a 20% growth in clinics piloting the combination therapy approach, indicating strong potential for future adoption and market expansion.
- Revenue for the second quarter of 2025 was $3.4 million, a significant decrease from $11.8 million in the same period in 2024, primarily due to distributor transitions and reduced sales.
- The company is experiencing short-term disruptions due to its strategic pivot, including transitioning away from certain distribution partners.
- Gross profit decreased to $2.5 million or 74% of revenue, down from $9.0 million or 76% of revenue in the same period in 2024, driven by decreased sales.
- Allurion Technologies Inc (ALUR) is re-evaluating its guidance for 2025 due to near-term disruptions from its new strategic direction.
- The company anticipates recording charges of approximately $1.5 million in the third quarter of 2025 related to its restructuring plan.
Hello and thank you for standing by. My name is Lacey and I will be your conference operator today. At this time, I would like to welcome everyone to the Allurion Second quarter earnings conference call. (Operator Instruction)
Thank you. I would now like to turn the conference over to Tara Brady. You may begin.
Good morning and thank you for joining us. Earlier today, Allurion Technologies Inc. Issued a press release announcing financial results for the quarter ended June 30, 2025 and provided a business update. You can access a copy of the announcement on the company's website at investors. allurion.com. With me on the call today, Shantanu Gaur, Founder and Chief Executive Officer.
Before we begin, I would like to inform you that comments mentioned on today's call contain forward-looking statements within the meeting of federal securities laws. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
